Biogen revenue rises 6.4 percent on Spinraza demand
July 25, 2017 at 06:45 AM EDT
(Reuters) - U.S. drugmaker Biogen Inc reported a 6.4 percent rise in quarterly revenue, driven by strong demand for its recently approved spinal muscular atrophy drug, Spinraza.
